Title: A Tale of Two Treatments: Antimalarials and the pursuit of legitimacy
Time: 10:00-12:30, 18 May 2017
Place: Salle J322, University of Paris Descartes
Seminar Series: Produire et inventer au sud
Abstract: Artemisinin-based combination therapies (ACTs) are the current front-line treatment for uncomplicated malaria recommended by the World Health Organization. Due to fears about the spread of artemisinin resistance in Sub-Saharan Africa, where the majority of malaria cases and deaths occur, the WHO and the Global Fund to Fight AIDS, TB, and Malaria mandate the use of combination therapies rather than monotherapies to protect the usefulness of the pharmaceutical agent. The WHO prequalifies pharmaceutical products and the Global Fund subsidizes only ant-imalarials that use different versions of the agent artemisinin (including artesunate, dihydroartemisinin (DHA or artenimol), and artemether) combined with other anti-malarial agents (like lumefantrine, amodiaquine, and mefloquine). In this global public health space where fear of losing pharmaceutical effectiveness drives much of the recommendations that the WHO promotes to fight malaria, I wish to investigate the modes of legitimization behind two “alternative” forms of producing anti-malarial treatments.